期刊
TRANSLATIONAL ONCOLOGY
卷 9, 期 4, 页码 340-347出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.tranon.2016.06.006
关键词
-
类别
资金
- Ministry of Science and Technology [MOST103-2325-B-037-005, MOST 103-2314-B-037-010-MY3]
- Kaohsiung Medical University Hospital [KMUH103-3M58, KMUH104-4M46, KMUH104-4M51]
- Center for Biomarkers and Biotech Drugs
- Kaohsiung Medical University
- Aim for the Top Universities Grant [KMU-TP104C00, KMU-TP104C01, KMU-TP104C02]
- Grant of Biosignature in Colorectal Cancers, Academia Sinica, Taiwan
- Excellence for Cancer Research Center Grant
- Ministry of Health and Welfare [MOHW105-TDU-B-212-134007]
- Health and welfare surcharge of tobacco products, Taiwan, Republic of China
Colorectal cancer (CRC) is a major public health problem. Early CRC detection, pretherapeutic responsiveness prediction, and postoperative micrometastasis monitoring are the hallmarks for successful CRC treatment. Here, the methodologies used for detecting circulating tumor cells (CTCs) from CRC are reviewed. In addition to the traditional CRC biomarkers, the persistent presence of posttherapeutic CTCs indicates resistance to adjuvant chemotherapy and/or radiotherapy; hence, CTCs also play a decisive role in the subsequent relapse of CRC. Moreover, the genetic and phenotypic profiling of CTCs often differs from that of the primary tumor; this difference can be used to select the most effective targeted therapy. Consequently, studying CTCs can potentially individualize treatment strategies for patients with CRC. Therefore, CTC detection and characterization may be valuable tools for refining prognosis, and CTCs can be used in a real-time tumor biopsy for designing individually tailored therapy against CRC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据